Toggle light / dark theme

Evolutionary genomics approach identifies genes that enable plants to live in the Atacama Desert, offering clues for engineering more resilient crops to face climate change.

An international team of researchers has identified genes associated with plant survival in one of the harshest environments on Earth: the Atacama Desert in Chile. Their findings, published in Proceedings of the National Academy of Sciences (PNAS), may help scientists breed resilient crops that can thrive in increasingly drier climates.

“In an era of accelerated climate change, it is critical to uncover the genetic basis to improve crop production and resilience under dry and nutrient-poor conditions,” said Gloria Coruzzi, Carroll & Milton Petrie Professor in the New York University (NYU) Department of Biology and Center for Genomics and Systems Biology, who co-led the study with Rodrigo Gutiérrez.

Rare diseases aren’t so rare. Collectively, up to 30 million Americans, many of them children, are born with one of the approximately 7,000 known rare diseases. Most of these millions of people also share a common genetic feature: their diseases are caused by an alteration in a single gene.

Many of these alterations could theoretically be targeted with therapies designed to correct or replace the faulty gene. But there have been significant obstacles in realizing this dream. The science of gene therapy has been making real progress, but pursuing promising approaches all the way to clinical trials and gaining approval from the U.S. Food and Drug Administration (FDA) is still very difficult. Another challenge is economic: for the rarest of these conditions (which is most of them), the market is so small that most companies have no financial incentive to pursue them.

To overcome these obstacles and provide hope for those with rare diseases, we need a new way of doing things. One way to do things differently—and more efficiently—is the recently launched Bespoke Gene Therapy Consortium (BGTC). It is a bold partnership of NIH, the FDA, 10 pharmaceutical companies, and several non-profit organizations [1]. Its aim: optimize the gene therapy development process and help fill the significant unmet medical needs of people with rare diseases.

It’s the dog days of summer. You bite down on a plump, chilled orange. Citrus juice explodes in your mouth in a refreshing, tingling burst. Ahh.

And congratulations—you’ve just been vaccinated for the latest virus.

That’s one of the goals of molecular farming, a vision to have plants synthesize medications and vaccines. Using genetic engineering and synthetic biology, scientists can introduce brand new biochemical pathways into plant cells—or even whole plants—essentially turning them into single-use bioreactors.

“De-Extinction” Biotechnology & Conservation Biology — Ben Novak, Lead Scientist Revive & Restore


Ben Novak is Lead Scientist, at Revive & Restore (https://reviverestore.org/), a California-based non-profit that works to bring biotechnology to conservation biology with the mission to enhance biodiversity through the genetic rescue of endangered and extinct animals (https://reviverestore.org/what-we-do/ted-talk/).

Ben collaboratively pioneers new tools for genetic rescue and de-extinction, helps shape the genetic rescue efforts of Revive & Restore, and leads its flagship project, The Great Passenger Pigeon Comeback, working with collaborators and partners to restore the ecology of the Passenger Pigeon to the eastern North American forests. Ben uses his training in ecology and ancient-DNA lab work to contribute, hands-on, to the sequencing of the extinct Passenger Pigeon genome and to study important aspects of its natural history (https://www.youtube.com/watch?v=pK2UlLsHkus&t=1s).

Ben’s mission in leading the Great Passenger Pigeon Comeback is to set the standard for de-extinction protocols and considerations in the lab and field. His 2018 review article, “De-extinction,” in the journal Genes, helped to define this new term. More recently, his treatment, “Building Ethical De-Extinction Programs—Considerations of Animal Welfare in Genetic Rescue” was published in December 2019 in The Routledge Handbook of Animal Ethics: 1st Edition.

Ben’s work at Revive & Restore also includes extensive education and outreach, the co-convening of seminal workshops, and helping to develop the Avian and Black-footed Ferret Genetic Rescue programs included in the Revive & Restore Catalyst Science Fund.

Ben graduated from Montana State University studying Ecology and Evolution. He later trained in Paleogenomics at the McMaster University Ancient DNA Centre in Ontario. This is where he began his study of passenger pigeon DNA, which then contributed to his Master’s thesis in Ecology and Evolutionary Biology at the University of California Santa Cruz. This work also formed the foundational science for de-extinction.

Ben also worked at the Australian Animal Health Laboratory–CSIRO (Commonwealth Scientific and Industrial Research Organisation) to advance genetic engineering protocols for the pigeon.

VR can soon become perceptually indistinguishable from the physical reality, even superior in many practical ways, and any artificially created “imaginary” world with a logically consistent ruleset of physics would be ultrarealistic. Advanced immersive technologies incorporating quantum computing, AI, cybernetics, optogenetics and nanotech would make this a new “livable” reality within the next few decades. Can this new immersive tech help us decipher the nature of our own “b… See more.

Researchers at MIT and Harvard University have designed a way to selectively turn on gene expression in target cells, including human cells. Their technology can detect specific mRNA sequences (represented in the center of the illustration), which triggers production of a specific protein (bottom right). Credit: Jose-Luis Olivares, MIT, with figures from iStockphoto.

“This brings new control circuitry to the emerging field of RNA therapeutics, opening up the next generation of RNA therapeutics that could be designed to only turn on in a cell-specific or tissue-specific way,” says James Collins, the Termeer Professor of Medical Engineering and Science in MIT’s Institute for Medical Engineering and Science (IMES) and Department of Biological Engineering and the senior author of the study.

This highly targeted approach, which is based on a genetic element used by viruses to control gene translation in host cells, could help to avoid some of the side effects of therapies that affect the entire body, the researchers say.

A commonly available oral diuretic pill approved by the U.S. Food and Drug Administration may be a potential candidate for an Alzheimer’s disease treatment for those who are at genetic risk, according to findings published in Nature Aging. The research included analysis showing that those who took bumetanide — a commonly used and potent diuretic — had a significantly lower prevalence of Alzheimer’s disease compared to those not taking the drug. The study, funded by the National Institute on Aging (NIA), part of the National Institutes of Health, advances a precision medicine approach for individuals at greater risk of the disease because of their genetic makeup.

The research team analyzed information in databases of brain tissue samples and FDA-approved drugs, performed mouse and human cell experiments, and explored human population studies to identify bumetanide as a leading drug candidate that may potentially be repurposed to treat Alzheimer’s.

“Though further tests and clinical trials are needed, this research underscores the value of big data-driven tactics combined with more traditional scientific approaches to identify existing FDA-approved drugs as candidates for drug repurposing to treat Alzheimer’s disease,” said NIA Director Richard J. Hodes, M.D.

An international team of researchers wants to find people who are genetically resistant to SARS-CoV-2, in the hope of developing new drugs and treatments.


Imagine being born naturally resistant to SARS-CoV-2, and never having to worry about contracting COVID-19 or spreading the virus. If you have this superpower, researchers want to meet you, to enrol you in their study.

As described in a paper in Nature Immunology1 this month, an international team of scientists has launched a global hunt for people who are genetically resistant to infection with the pandemic virus. The team hopes that identifying the genes protecting these individuals could lead to the development of virus-blocking drugs that not only protect people from COVID-19, but also prevent them from passing on the infection.

“It’s a terrific idea,” says Mary Carrington, an immunogeneticist at the Frederick National Laboratory for Cancer Research in Bethesda, Maryland. “Really, a wise thing to do.”

The non-E5 made rats healthier with a small increase in lifespan. The E5 part 2 is still ongoing with rats at 31 months that generally at most live 36 months.


In this video we give a brief update on the parallel experiments being conducted by Dr Katcher and Professor Goya. In these studies they are injecting E5 and young blood plasma into rats in repeatedly to see if the maximum lifespan can be extended.

The newsletter is here.
https://www.ntzplural.com/newsletter.

Papers mentioned in this video.
The original paper on BioXriv.
Reversing age: dual species measurement of epigenetic age with a single clock.
https://www.biorxiv.org/content/10.1101/2020.05.07.082917v1
********************************************
Health claims Disclosure: Information provided on this video is not a substitute for direct, individual medical treatment or advice. Please consult with your doctor first. Products or services mentioned in this video are not a recommendation.

Disclosure: Some of the links provided are affiliate links. Although we may receive a small commission from the affiliate, the cost of the product for you will always be the same, or often discounted. Thank you for supporting our channel.

*******************************************
Alive By Science — All products 10% Embedded Discount Code Link — https://tinyurl.com/w8mk2zc.
Direct link to Liposomal Glutathione.
https://tinyurl.com/emypha8y.

Alive By Science NAD test 10% discount.
https://tinyurl.com/4umms2nz.

~ New ~ Our Bone Health Supplement:
https://iherb.co/wJ14LbC BioGaia, Osfortis with Vitamin D, 60 Capsules.
iHerb New Customer 5% off.